The Food and Drug Administration decision paves the way for a speedy
regulatory review and confirms the drug's potential in earlier stage
disease, despite its initial failure in the key Mystic trial, which
targeted the bigger advanced cancer market.
(Reporting by Ben Hirschler, editing by Louise Heavens)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.